The fund size is US$150M. The primary investment areas focus on enterprise software, autonomous systems, AI, IoT, robotics & drones, information security, next-gen semiconductors, sensors, and cloud infrastructure.

With a fund size of US$200M, Fund II invests in companies with disruptive and advanced technologies which address unmet medical needs. The key investment thesis is to bridge Taiwan innovations with the global biotech industry.

With a fund size of US$59M, Fund III focuses on investments in Medtech startups that develop therapeutic/diagnostic devices or precision health-related medical technology. Taiwania will help Medtech startups to optimize their growth, new product launches, and new market entry.

The fund size is US$56M. The primary investment areas focus on early startups specialize in automation, enterprise SaaS, 5G and networking, advanced manufacturing, and digital health.

The fund size is US$200M. Focusing on topics such as new edge and 5G infrastructure, EV supply chain, Hybrid next generation Semi and data/ML security and lifecycle.

The target fund size is US$200 million.The fund is an international joint venture between Taiwania Capital and Axil Capital Group (“Axil”) based in Tokyo.The fund’s investment thesis focuses on areas such as rare diseases, gene and cell therapy, AI-driven medical devices, and first-in-class therapeutics, among others.

Entrusted by Taiwan’s National Development Council, Taiwania Capital manages the Central and Eastern Europe Investment Fund (the CEE Fund) from March 2022. The fund is dedicated to making equity investments in Taiwan and CEE companies, with the objective of buttressing Taiwan’s economic and investment ties with democratic allies in Europe. The CEE Investment Fund invests in Taiwan and CEE companies in strategically important sectors including semiconductor, laser optics, biotechnology, aerospace, fintech, EV, smart manufacturing, software development, and smart city. The fund is stage agnostic and will invest US$200 million in the coming years.